Contura Submits Registration Application for Aquamid(R) to the FDA


    


    
</pre>
<p>SOBORG, <span class="xn-location">Denmark</span>, <span class="xn-chron">April 15</span> /CNW/ -- Contura Inc. has submitted a Premarket Approval Application (PMA) for Aquamid® to the U.S. Food and Drug Administration (FDA) requesting marketing approval in the U.S. for the aesthetic treatment of moderate to severe facial wrinkles and folds.</p>
<p/>
<p>The application includes a successful U.S. pivotal study, in which the safety and efficacy of Aquamid was compared to Medicis' Restylane® for 12 months after treatment. The study results were presented last year at the American Society of Dermatologic Surgery's Annual Meeting and at Plastic Surgery 2009, and showed that Aquamid was as effective as Restylane® at 6 months follow-up based on the study endpoints and maintained this effectiveness at 12 months follow-up. Both treatments were safe and well tolerated. Also included in the application is a study extension that followed the Aquamid-treated subjects up to two years and demonstrated a consistent effectiveness and safety profile.</p>
<p/>
<p>If approved for the U.S. market, Aquamid will be produced at Contura's new manufacturing facility in <span class="xn-location">Denmark</span>, which was designed to meet FDA requirements, and was recently approved by the European authorities.</p>
<pre>
    

    About Aquamid
    
</pre>
<p>Aquamid is composed of 97.5% water for injection and 2.5% cross-linked polyacrylamide. The patented hydrogel is homogeneous: it contains no micro particles; hence its filling effect is due solely to the injected volume. Unlike particle-based fillers, the hydrogel does not rely on an intended foreign body reaction to achieve the desired augmentation. Therefore, the filling effect is immediate and predictable. Aquamid does not degrade over time and provides a choice for patients who are looking for a long lasting aesthetic solution. Aquamid was approved in <span class="xn-location">Europe</span> in 2001 for facial augmentation and minor body contouring and is available in several countries in <span class="xn-location">Europe</span>, Asia, the <span class="xn-location">Middle East</span> and Latin America. In those countries, Aquamid is used mainly for treating nasolabial folds, lip augmentation, cheek contouring, nose enhancement, and for treating facial lipoatrophy. More than a quarter of a million people have been treated with Aquamid. Aquamid is not yet approved for sale in the <span class="xn-location">United States</span>.</p>
<pre>
    

    About Contura
    
</pre>
<p>Contura is a medical technology company based in <span class="xn-location">Denmark</span> that develops, manufactures, and commercializes soft tissue fillers in compliance with the European regulatory requirements for medical devices. Contura's products -- Aquamid for facial contouring and Bulkamid® for the treatment of female urinary incontinence -- are manufactured using the company's patented polyacrylamide hydrogel technology. Aquamid is sold through a network of local distributors in several countries in <span class="xn-location">Europe</span>, Asia, the <span class="xn-location">Middle East</span> and Latin America. Ethicon Inc., a Johnson & Johnson company, holds the exclusive worldwide distribution rights for Bulkamid.</p>
<pre>
    

    www.contura.com
    www.aquamid.us

    
</pre>
<p> </p>
<p> </p>
<p>Media Contact</p>
<p> </p>
<pre>
    
    Ruder Finn
    Susan Smirnoff
    +1 212.593.6323
    smirnoffs@ruderfinn.com





    

For further information: For further information: Susan Smirnoff, Ruder Finn, +1-212-593-6323, smirnoffs@ruderfinn.com Web Site: http://www.contura.com

Organization Profile

CONTURA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890